Phase I, Pharmacokinetic and Pharmacodynamic Study of BAY 43-9006 (Sorafenib) in Combination With CCI-779 (Temsirolimus) in Advanced Solid Malignancies
Latest Information Update: 09 Dec 2015
At a glance
- Drugs Sorafenib (Primary) ; Temsirolimus
- Indications Solid tumours
- Focus Adverse reactions
- 01 Jul 2013 Actual initiation date changed from Oct 2005 to Sep 2005 as reported by ClinicalTrials.gov.
- 29 Jan 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.